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Key Points 
1. CCRL2 is required for CXCR2-dependent neutrophil recruitment in inflammation 
 
2. The administration of anti-CCRL2 moAb in WT animals reproduced the protective phenotype of 
CCRL2-deficient mice in experimental arthritis. 
 
 
 
 
 
Abstract  
 
CCRL2 is a seven transmembrane domain receptor that shares structural and functional similarities 
with the family of the Atypical Chemokine Receptors (ACKRs). CCRL2 is upregulated by 
inflammatory signals and, unlike from other ACKRs, is not a chemoattractant scavenging receptor, 
does not activate β-arrestins and is widely expressed by many leukocyte subsets. Therefore, the 
biological role of CCRL2 in immunity is still unclear. Here we report that CCRL2-deficient mice 
have a defect in neutrophil recruitment and are protected in two models of inflammatory arthritis. In 
vitro, CCRL2 was found to constitutively form homo and heterodimers with CXCR2, a main 
neutrophil chemotactic receptor. By heterodimerization, CCRL2 could regulate membrane 
expression and promote CXCR2 functions including the activation of β2-integrins. Therefore, 
upregulation of CCRL2 observed under inflammatory conditions is functional to finely tune 
CXCR2-mediated neutrophil recruitment at sites of inflammation.  
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Introduction 
Leukocyte recruitment is a hallmark of inflammation and depends on the local production of 
chemotactic factors and on the regulation of the chemotactic receptors expressed by leukocytes1,2. 
Among chemotactic factors, chemokines represent the main family of signals able to induce 
leukocyte recruitment in vitro and in vivo. CXCR2 is the major chemokine receptor responsible for 
neutrophil recruitment. CXCR2 engagement induces the rapid Gα
i
-dependent activation of 
phospholipase C (PLC)-β, phosphatidylinositol 3-kinase γ (PI3Kγ), guanine exchange factors for 
rho- and ras-small GTPases, talin and kindlin-3, a signaling cascade promoting rapid β2-integrin 
clustering as well as conformational changes leading to increased affinity. This process allows the 
arrest and crawling of neutrophils on the surface of the endothelial cell monolayer and their 
extravasation3-5. 
Atypical chemokine receptors (ACKRs) represent a small subset of proteins that express a 
high degree of homology with chemokine receptors. However, ACKRs lack structural determinants 
supporting Gαi signaling, making them unable to activate canonical G protein-dependent receptor 
signaling and cell migration6. At the moment, the ACKR family includes four proteins, namely 
ACKR1 (Duffy antigen receptor for chemokines-DARC), ACKR2 (D6 or CCBP2), ACKR3 
(CXCR7 or RDC1) and ACKR4 (CCRL1 or CCXCKR and CCR11). In virtue of their ability to 
bind chemokines, ACKRs were shown to regulate inflammation acting as scavenger receptors, 
promoting chemokine transcytosis or regulating chemokine gradient formation6-9. 
CCRL2 is a seven transmembrane protein that shares some structural and functional aspects 
with ACKRs, such as the lack of conventional GPCR signaling and the inability to induce cell 
migration6,10,11. CCRL2 is expressed by barrier cells, such as endothelial and epithelial cells, and by 
a variety of leukocytes, including macrophages, dendritic cells and neutrophils6,10. CCRL2 was 
shown to bind and present chemerin, a non-chemokine chemotactic protein, to leukocytes 
expressing ChemR23, the functional chemerin receptor, a function that may be relevant for 
leukocyte extravasation12,13. CCRL2 expression is upregulated by inflammatory signals but its 
function remains unclear. This study was performed to investigate the role of CCRL2 in 
neutrophils, a leukocyte subset known to play a crucial role in the innate defense against pathogens 
and also involved in pathological conditions, such as cancer and autoimmune disorders (e.g. 
rheumatoid arthritis)2,14,15. Here we report the ability of CCRL2 to regulate neutrophil migration and 
describe a new strategy by which atypical chemotactic receptors may control leukocyte trafficking 
into inflamed tissues. 
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Methods 
 
Mice 
CCRL2-deficient mice (KO) (C57BL/6J)16 did not show altered expression of other chemokine 
receptors and adhesion molecules (Supplemental Figure 1). Age- and sex-matched littermates or 
control C57/BL6J, and DBA1 mice purchased from Charles River Lab. Procedures involving 
animals conformed to institutional guidelines in compliance with national (D.L. N.26, 4-3-2014) 
and international (Directive 2010/63/EU revising Directive 86/609/EEC, September 22, 2010) law 
and policies.  
 
Flow cytometry analysis 
Bone marrow (BM) cells were CD16/32 (2.4G2) blocked and stained with the following moAbs: 
CD11b (M1/70), Ly6G (1A8), and F4/80 (BM8) from BD Pharmingen; anti-mouse CCRL2 (11n20) 
from LSBio; anti-mouse CXCR2-AlexaFluor647 (SA045E1) from Biolegend. Anti-ERK1/2 
(T202/Y204) moAb from BD Pharmigen. Anti-active Rac1-GTP and anti-RhoA-GTP from 
NewEast Biosciences. Cells were acquired with MACSQuant (Miltenyi), or LSR Fortessa flow 
cytometer (BD Biosciences) and analysed by FlowJo software. 
 
BM neutrophils isolation 
BM neutrophils were isolated by negative selection using the neutrophil isolation kit (Miltenyi). 
The purity of the neutrophil population was routinely more than 90% CD11b+Ly6G+ cells.  
 
Chemotaxis  
Cell migration was evaluated using a 48-well chemotaxis chamber (Neuroprobe) and polycarbonate 
filters (5μ pore size; Neuroprobe) for 50-minute incubation as described17. Results are expressed as 
number of migrated cells in an average of 5 high-power fields (100x).  
 
Ca2+ mobilization 
Purified neutrophils (3.75x106 cells/ml) were loaded with Fluo-8 No Wash dye (Cat# 36316, AAT 
Bioquest®, Inc.) for 60 min at RT. Ca2+ mobilization in response to CXCL8 was measured by using 
a fluorometric-imaging plate reader (FLIPRTETRA, Molecular Devices).  
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In vivo leukocytes mobilization 
The recruitment of leukocytes into the peritoneal cavity after i.p. administration of human CXCL8 
(300 ng) or LPS (15 ng)18 at the indicated time points was analyzed in control and CCRL2-deficient 
mice by flow cytometry. Human CXCL8 is known to activate murine CXCR219 although with a 
lower affinity than other CXCR2 mouse ligands20. 
 
Experimental Arthritis 
Collagen-Induced Arthritis (CIA) was induced in 8- to 12-week-old male CCRL2-deficient and 
control mice as previously described21. CIA was induced in DBA1 mice with 100 μg denatured type 
II bovine collagen (MD Biosciences) emulsified in CFA. For the induction of Serum-Transfer 
Induced Arthritis (STIA), mice were i.p. administered with 150 μl serum from K/BxN transgenic 
mice (kindly provided by D. Mathis and C. Benoist)22. Paws were scored for disease severity as 
described 21. At the end of the experiment, the joints were removed, fixed, decalcified, and paraffin 
embedded. Sections (4 μm) were stained with H&E and Ly6G. Antigen-induced arthritis was 
induced by intradermally immunization with metBSA as previously described23. Anti-collagen 
antibodies in mouse sera were measured by Arthrogen-CIA ELISA kit (Chondrex)21. 
 
BM transplantation 
Control or CCRL2-deficient mice were lethally irradiated with a total dose of 9 Gy. Then, 2 hrs 
later, mice were injected in the tail vein with 5×106 nucleated control or CCRL2-deficient BM cells. 
At 8 weeks after bone marrow transplantation, the STIA model was performed. 
 
Real-time PCR 
Total RNA was extracted with RNeasy kit (Quiagen). Real-time quantitative PCR reactions were 
performed on a MJ Real Time PCR system (Biorad), using a SYBR Green PCR master mix 
(Applied Biosystems)16.  
 
Under-flow adhesion assay  
Neutrophil behavior in underflow conditions was studied with the BioFlux 200 system (Fluxion 
Biosciences). 48-well plate microfluidics were first co-coated overnight at RT with 2.5 μg/ml 
murine E-selectin and 5 μg/ml murine ICAM-1 in PBS. Before use, microfluidic channels were 
washed with PBS and then coated with 4 μM CXCL8 for 3 hrs at RT and the assay was done at 
shear stress of 2 dyne/cm2 24.  
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Intravital Microscopy  
Intravital microscopy was performed in the synovial microcirculation of mouse knee, as 
described23. Briefly, the left hind limb was placed on a stage, the patellar tendon mobilized and 
partly resected, and the intraarticular knee synovial tissue visualized. To measure the leukocyte–
endothelial cell interactions, the fluorescent marker rhodamine 6G (Sigma) was i.v. injected (0.15 
mg/kg) before the measurements. Images were captured with an Axiocam 503 Mono digital camera 
(Zeiss).  
 
Elastase release 
BM neutrophils (107 cells/ml) preincubated with cytochalasin B were treated with CXCL8 or 
CXCL1. Elastase release was determined as elastase activity measured in conditioned cell media 
and fluorescence was monitored (370/460nm, EnSight™ Multimode Plate Reader, PerkinElmer).  
 
Time-lapse microscopy assay 
BM purified neutrophils were o/n LPS stimulated, then seeded on matrigel pre-coated glass plate. 
Micropipette (FemtotipII, Eppendorf) was loaded with 10μl of CXCL8 (100μg/ml) and injected at 
15hPa pressure. Acquisition was performed with Axio Cam MRm (Zeiss Microscopy).  
 
FRET experiments 
For homodimer studies HEK293T cells were cotransfected with a constant amount of CXCR2-CFP 
(1.5μg/well, 3x105 cells) and increasing amounts of CXCR2-YFP (0.125-4.5μg/well)25 or CCRL2-
CFP (1μg/well) and CCRL2-YFP (0.15-2.0μg/well). For heterodimer determinations CCRL2-CFP 
(1.5μg/well) and CXCR2-YFP (0.25-5.5μg/well) were used. To determine the spectral signature, 
cells were transiently transfected with CFP or YFP26. For FRET determination by photobleaching, 
HEK293T cells were transiently cotransfected with CCRL2-CFP (0.2 μg/well for 3.5x104 
cells)/CXCR2-YFP (0.8 μg/well). Cells (3.5x104 cells/well), cultured in coverslip chambers (Nunc) 
precoated with fibronectin were imaged 48 h after cDNA transfection25. To establish the influence 
of CCRL2 expression on CXCR2/CXCR2 homodimers in FRET saturation curves, cells were 
transiently transfected with pcDNA3.1 (pcDNA, empty vector) or pcDNACCRL2. At 24 hrs post-
transfection, these cells were cotransfected with CXCR2-CFP (1.5 μg/well, 3x105 cells) and 
CXCR2-YFP (0.125-4.5 μg/well).  
 
 
 
For personal use only.on August 8, 2018. by guest  www.bloodjournal.orgFrom 
Del Prete et al-Revised      7 
 
Statistical analyses 
Statistical analyses were performed using Student t test, Mann-Whitney U test, and two-way 
analysis of variance (ANOVA), as appropriate. Results were analyzed using GraphPad PRISM 5.0.  
For personal use only.on August 8, 2018. by guest  www.bloodjournal.orgFrom 
Del Prete et al-Revised      8 
 
Results 
 
Neutrophil recruitment is defective in CCRL2-deficient mice 
Freshly isolated mouse neutrophils were found to express basal levels of membrane CCRL2. 
Culturing neutrophil in the absence of stimulation induced CCRL2 downregulation (105±11 and 
57±10, MFI±SEM of fresh vs. 18 hrs cultured neutrophils). On the contrary, overnight stimulation 
with LPS or with the combination of pro-inflammatory agonists (i.e. LPS, TNFα and IFNγ), caused 
a strong increase in CCRL2 expression with the majority of the cells co-expressing CCRL2 and 
CXCR2 (Fig. 1A). Chemotactic agonists, namely fMLP, C5a and CXCL8 did not regulate CCRL2 
expression (data not shown). To investigate the biological role of CCRL2, neutrophil recruitment 
was evaluated in vivo two hrs after the intraperitoneal injection of LPS. A marked reduction in 
neutrophil count was observed in CCRL2-deficient mice, compared to WT animals (Fig. 1B, left 
panel). Of note, at this time point, the expression of CCRL2 was already upregulated in the cells 
recovered from the peritoneal cavity of WT mice (Fig. 1B, right panel). A marked reduction of 
neutrophil recruitment was also observed in response to the intraperitoneal injection of CXCL8 
(Fig. 1C) and after the administration of methylated bovine serum albumin into the knee joint of 
previously immunized CCRL2-deficient mice (Fig. 1D). These results were not due to reduced bone 
marrow mobilization, since similar numbers of CD11b+/Ly6G+ cells were detected in the bone 
marrow and in circulation of WT and CCRL2-deficient mice after CXCL8 administration 
(Supplementary Fig. 2).  
  
CCRL2-deficient mice are protected in experimental models of inflammatory arthritis 
Different mouse models of experimental arthritis have highlighted the crucial role of 
neutrophils in the development of inflammatory joint diseases. Neutrophil recruitment to the 
inflamed joint is accomplished through the sequential activation of multiple chemokine receptors, 
which involves first the receptor for the lipid inflammatory mediator leukotriene B4 (LTB4) and 
then the chemokine receptors CXCR1/CXCR2 and CCR123,27,28. 
CCRL2-deficient mice were tested first in the model of collagen-induced arthritis to study 
the priming phase, consisting in the activation of the specific immune response to collagen type II, 
as well as the inflammatory effector phase of the disease, characterized by local inflammation, 
cartilage and joint destruction29. Figure 2A shows that CCRL2-deficient mice were protected and 
developed arthritis with a lower incidence compared to WT controls (16.67% vs. 34.48% 
respectively; data not shown). CCRL2-deficient mice showed also a statistical significant delay in 
the onset of the disease (day +25 vs. day +20, in CCRL2 KO vs. WT mice, respectively) and a 
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marked decrease in its severity. Consistent with these results, histopathological examination 
highlighted a marked reduction in synovial inflammation, pannus formation and erosion of the 
articular cartilage (Fig. 2B and C). The reduced severity of disease observed in CCRL2-deficient 
mice was not associated with changes in anti-collagen type II antibody serum levels (Fig. 2D), 
suggesting that CCRL2-associated protection is mostly confined to the inflammatory effector phase 
rather than on the induction phase of the disease. Of interest, the repeated administration of an anti-
CCRL2 moAb to DBA1 mice, a strain more susceptible to CIA (100% incidence at day 36) than 
C57BL/6 mice30, produced a degree of protection comparable to that observed in CCRL2-deficient 
animals (Fig. 3A).  
The effector phase of arthritis was further investigated using the experimental model of the 
K/BxN serum transfer-induced arthritis (STIA)31. STIA is a more rapid and aggressive model than 
CIA that it was found to be suitable for the preclinical study of new therapeutic strategies32. Fig. 3B 
depicts that also in this model, the appearance of the clinical symptoms was delayed in CCRL2-
deficient mice with a maximal clinical score at the peak of disease (day +4) that was only 43 % of 
that observed in WT animals. Also in the STIA model, the administration of an anti-CCRL2 moAb 
induced in WT animals a degree of protection that was similar to that observed in CCRL2-deficient 
mice. Immunohistochemical analysis of Ly6G+ cells revealed that neutrophil infiltration was 
strongly reduced in CCRL2 KO and in WT mice treated with an anti-CCRL2 moAb, compared to 
WT mice (Fig 3C). At day +4, the circulating levels of IL-6, a systemic marker of inflammation, 
were significantly reduced in CCRL2-deficient mice, as well as the levels of the neutrophil 
chemotactic cytokines CXCL1 and CXCL2 and the T cell attracting chemokine CCL5. As expected 
based on previous work 33, in CCRL2 KO mice, serum levels of chemerin were increased by 26.7% 
(Fig. 3D). 
Bone marrow chimera obtained by WT and CCRL2-deficient bone marrow transfer 
identified hematopoietic cells as the major component conferring protection in KO mice in STIA. 
Indeed, transplantation of CCRL2-deficient bone marrow cells in WT mice recapitulated the 
protective phenotype observed in KO mice transplanted with CCRL2-deficient bone marrow cells, 
while transplantation of WT bone marrow cells in KO mice abolished the protective phenotype 
(Supplementary Fig. 3). Finally, adoptive transfer of WT, but not CCRL2-deficient neutrophils 
abolished the protection of CCRL2-deficient mice, identifying these cells as the main CCRL2-
expressing population responsible for the protective phenotype observed in CCRL2-deficient mice 
(Fig. 3E).  
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CCRL2-deficient neutrophils are defective in CXCR2-mediated signaling 
To investigate the mechanisms responsible for the defective in vivo neutrophil migration, a 
more detailed analysis was performed by intravital microscopy using the model of metBSA-induced 
arthritis. As shown in Figure 4A, 24 hrs after the administration of the antigen into the knee of 
immunized WT mice, numerous cells were found adherent to the vessels located in the knee that 
received the antigen (left knee). No adherent cells were observed in the control joint (right knee) 
that received only saline (see also Supplementary Movie 1 and 2). On the contrary, the inflamed 
joints (left knee) of CCRL2-deficient animals showed a strong reduction of endothelial cell-
adherent leukocytes, with the majority of the cells undergoing the rolling process on the endothelial 
layer (Figure 4A and Supplementary Movie 3 and 4). These results strongly suggested that CCRL2-
deficient neutrophils may have a defect in integrin mediated arrest. 
To address this hypothesis, the ability of bone marrow-purified neutrophils to undergo 
rolling and adhesion was investigated in vitro under flow conditions. At the shear stress of 2 
dyne/cm2, which resembles the physiological shear stress normally acting in postcapillary venules, 
CCRL2-deficient neutrophils showed a defective ability to undergo rapid (1 sec) arrest on E-
selectin-, ICAM-1- and CXCL8-coated glass capillaries. As expected, a higher number of rolling 
cells was counted using CCRL2 KO neutrophils compared to WT cells (Fig. 4B). This defect was 
best observed at the very early time points of arrest, becoming much less dramatic when the arrest 
parameter was set at 10 secs, a time point more likely consistent with phenomena of post-binding 
stabilization and, possibly, outside-in signaling. Consistent with in vivo findings (Fig. 3), treatment 
with an anti-CCRL2 moAb recapitulated the defective arrest observed with CCRL2-deficient 
neutrophils (Fig. 4B). These findings clearly support the concurrent regulatory cooperation of 
CCRL2 and CXCR2 in triggering β2-integrin activation and mediated rapid arrest. 
To better understand the molecular basis for the defective cell adhesion, the CXCR2-
mediated signaling was investigated. Stimulation of freshly isolated CCRL2-deficient neutrophils 
with CXCL8 produced lower levels of phospho-ERK along the entire kinetics investigated, when 
compared to WT cells (Fig. 4C). This defect was specific for CXCL8, since normal ERK1/2 
phosphorylation was observed in CCRL2-deficient cells stimulated with CCL3, LTB4 or PMA 
(Supplementary Fig. 4). Similarly, CXCL8-stimulated CCRL2-deficient neutrophils showed 
defective phosphorylation of RhoA and Rac1 small GTPases, two key elements in chemotactic 
receptor signaling (Fig. 4D and E). Consistently with these results, the ability of CXCL8 to induce 
calcium fluxes was reduced in CCRL2-deficient neutrophils compared to WT cells starting at 
concentrations as low as 30 nM CXCL8 with respective EC50 values of 125.4 nM and 251.0 nM 
CXCL8 (Fig. 4F).  
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CCRL2 KO neutrophils also displayed reduced release of elastase in response to CXCL8 or 
CXCL1, but not in response to fMLP (Fig. 5A and data not shown). On the contrary, neutrophil 
chemotaxis, investigated in vitro using the modified Boyden chamber assay, showed a normal 
migration of CCRL2-deficient cells in response to a panel of chemotactic agonists, including lipids 
(i.e. LTB4
 
and platelet activating factor) and chemokines (i.e. CXCL1, CXCL8 and CCL3). No 
migration of WT or CCRL2-deficient neutrophils was observed in response to the chemotactic 
protein chemerin, confirming the lack of expression of ChemR23 by both resting and activated 
neutrophils (Fig. 5B and data not shown)34. Using time-lapse microscopy migration assays, 
CCRL2-deficient neutrophils showed a normal ability to orient and migrate to a CXCL8 gradient on 
a matrigel-coated surface (Fig. 5C, left panel)35. However, following LPS activation, which 
upregulates CCRL2 expression (Fig. 1), CCRL2-deficient neutrophils revealed a reduced velocity 
in response to a CXCL8 gradient, compared to WT cells, suggesting that the upregulation of 
CCRL2 is associated with a positive regulation of the chemotactic response to CXCL8 possibly 
related to a better interaction of WT cells with extracellular matrix components (Fig. 5E, right 
panel).  
 
CCRL2 and CXCR2 form both homodimers and heterodimers 
 Heterodimers between receptors have been proposed as a mechanism that modulates 
chemokine functions36-39. To investigate the molecular basis of CCRL2 regulation of CXCR2 
signaling and function we evaluated the possibility that these two receptors, when co-expressed, 
may form heterodimers. We generated FRET saturation curves using HEK293T cells transiently 
cotransfected with constant amounts of donor (CXCR2- or CCRL2-CFP) and increasing amounts of 
acceptor (CXCR2- or CCRL2-YFP). Positive FRET was observed for CXCR2 and CCRL2 
homodimers (Fig. 6A and B) and for CCRL2/CXCR2 heterodimers (Fig. 6C).  As a negative 
control, we used the Histamine 3 receptor (H3R), indicating the specificity of the interaction 
between CCRL2 and CXCR2 (Fig. 6A and B). 
To corroborate these data and to determine the intracellular localization of the heterodimeric 
complexes, we transiently cotransfected HEK293T cells with CCRL2-CFP (donor) and CXCR2-
YFP (acceptor) at a YFP/CFP ratio at which the FRET50 signal was detected in saturation curves 
(Fig. 6C), and determined FRET by the acceptor photobleaching method. To verify that transfection 
ratios corresponded to the equivalent YFP/CFP ratio determined, we measured YFP and CFP 
fluorescence separately in each image. CCRL2 and CXCR2 heterodimers were detected both at the 
cell membrane and in the cytoplasm (Fig. 6D), confirming heterodimerization between the two 
receptors and suggesting the existence of a pool of receptors retained intracellularly. Of note, FRET 
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efficiency was higher for the intracellular complexes indicating differences in the conformation of 
the heterodimer depending on the cell localization evaluated. The intracellular retention of 
CCRL2/CXCR2 complexes was confirmed by FACS using an anti-CXCR2 specific moAb. The 
levels of CXCR2 at the cell membrane were reduced by 25.8% when HEK293T cells were co-
transfected with CCRL2 (Fig. 6E). In agreement with these data, freshly isolated neutrophils 
obtained from CCRL2-deficient mice were characterized by a corresponding increase of membrane 
MFI when stained with an anti-CXCR2 moAb, suggesting the KO cells express higher levels of 
membrane CXCR2 than WT neutrophils (Fig. 6F). 
 
CCRL2 expression modulates CXCR2 homodimeric complexes 
FRET was also used to determine whether CCRL2 expression influences CXCR2 
homodimer conformation. HEK293T cells were transfected with CCRL2 or empty vector, then 
cotransfected with constant amounts of CXCR2-CFP (donor) and increasing amounts of CXCR2-
YFP (acceptor). The CCRL2 expression was analyzed by flow cytometry at each CXCR2-
YFP/CXCR2-CFP ratio (Fig. 7A and data not shown). CCRL2 significantly altered FRET 
saturation curves for CXCR2 homodimer complexes, as indicated by the change in the FRET50 
values (3.52 ± 0.85 for CXCR2-CFP/CXCR2-YFP + pcDNA3.1 and 2.04 ± 0.56 for CXCR2-
CFP/CXCR2-YFP + pcDNA3.1 CCRL2) (P<0.05) whereas FRETmax values were unchanged (Fig. 
7B and C). Energy transfer efficiency depends on the relative orientation and distance between the 
CXCR2-coupled fluorescent proteins; modifications in the FRET50 values indicate changes in the 
apparent affinity between the two partners and suggest that CCRL2 coexpression alters CXCR2 
homodimers.  
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Discussion 
 
Inflammation is characterized by the regulated recruitment of leukocytes at the site of injury, 
with neutrophils usually being the first recruited cell population15,40. The results presented here 
show that the expression of CCRL2 is critical for full CXCR2 signaling and β2-integrin activation 
in stimulated neutrophils.  
The relevance of CCRL2 upregulation under inflammatory conditions is well documented 
by the use of CCRL2-deficient mice in two models of inflammatory arthritis. These models directly 
rely on neutrophil recruitment23,27,28,41. CCRL2-deficient mice were strongly protected in terms of 
onset, tissue damage and severity of the disease, with respect to WT animals. Of note, the 
administration of an anti-CCRL2 moAb to WT mice induced a degree of protection comparable to 
that observed in CCRL2-deficient animals. The two experimental models of arthritis used involve 
the action of multiple effector cells, including macrophages and mast cells32. By adoptive transfer 
experiments performed in the STIA model we have excluded a role of CCRL2 expression in mast 
cells (data not shown), although we cannot exclude the involvement of other CCRL2+ effector cells. 
However, since the adoptive transfer of WT neutrophils reversed the protective phenotype of 
CCRL2 KO mice, neutrophils are likely to be the main cell subset regulated by CCRL2 expression 
in STIA. CCRL2 mRNA was reported to be expressed by neutrophils purified from the synovial 
fluid of rheumatoid arthritis patients42. Although human neutrophils differ from the murine 
counterpart in many aspects, including membrane markers, cytokine production and functions43,44, 
these results candidate CCRL2 as a novel potential target in rheumatoid arthritis possibly to be 
exploited as a complementary therapy in low-responder patients45,46. 
CXCR2-mediated signaling was impaired in CCRL2-deficient neutrophils and this defect is 
likely to be responsible for the reduced activation of β2-integrins. In this context it is interesting to 
note that β2-integrin expression on neutrophils was reported to be crucial for arthritis development 
in STIA47. In the attempt to clarify the molecular mechanisms responsible for this effect, it was 
observed that CCRL2 and CXCR2 form homo and heterodimers. CCRL2/CXCR2 
heterodimerization was found to regulate CXCR2 membrane expression and signaling, and to 
modulate the formation of CXCR2 homodimeric complexes.  
GCPRs, including chemokine receptors, are known to form homo and heterodimers and this 
process is known to regulate their functions, including intracellular trafficking and signaling 
pathways36-39,48. Two members of the ACKR family were previously reported to form both homo 
and heterodimers. ACKR1 can constitutively form heterodimers with CCR5, a receptor with which 
it shares the ligand, namely CCL56. The functional result of ACKR1/CCR5 heterodimerization is 
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the inhibition of CCR5 signaling and activity49. Similarly, ACKR3 forms constitutive heterodimers 
with CXCR4, a receptor with which it shares the ligand, CXCL12. The formation of 
ACKR3/CXCR4 heterodimers was reported to be crucial for CXCL12-induced intracellular 
signaling (e.g. calcium flux and ERK1/2 phosphorylation)37,38. Thus, ACKR1 and ACKR3 can form 
oligomers with receptors with which they share the same ligand. In this scenario, CCRL2 is 
apparently unique among the atypical chemotactic receptors, since it forms heterodimers and 
regulates the function of CXCR2, the receptor for CXCL8, a chemokine that does not bind CCRL2.  
Chemokines have fundamental roles in regulating immune and inflammatory responses and 
during evolution several strategies developed to control their biological activity6,8,50, ACKRs being 
one of such strategies. In contrast to classic chemokine receptors, ACKRs are generally expressed 
by non-leukocyte cell types, such as barrier cells (i.e. epithelial and endothelial cells) and do not 
activate G protein-dependent signaling6,8,9,51. Rather, upon binding of their ligands, ACKRs 
transport chemokines to intracellular degradative compartments or in certain cell types, to the 
opposite side of the cell monolayer by a β-arrestin-dependent pathway52,53. These scavenging 
properties make ACKRs important molecules in the regulation of the inflammatory response1,9. At 
difference from the other ACKRs, CCRL2 is expressed by leukocytes, including macrophages, 
dendritic cells, mast cells, microglia and neutrophils. In addition, CCRL2 does not apparently 
internalize in a constitutive manner or activate β-arrestin-dependent pathways10-12. Nevertheless, 
CCRL2 was reported to regulate the immune response in a model of IgE-mediated cutaneous 
anaphylaxis and in a model of lung hypersensitivity12,16. In this regard it is interesting to note that in 
CCRL2-deficient mice, lung dendritic cells were reported to be defective in their migration to 
mediastinal lymph nodes16, a process known to be dependent on CCR7 and CCR854. Therefore, it is 
tempting to speculate that CCRL2 might also regulate the function of other chemokine receptors.  
 In conclusions, these results identify a novel pathway of regulation of neutrophil recruitment 
dependent on the expression of the atypical receptor CCRL2. Although in vivo we cannot formally 
exclude the involvement of other receptors, our data strongly suggest that CXCR2 is a main target 
of CCRL2 regulation. The spectrum and structural components of CCRL2 tuning functions still 
remain to be fully elucidated. Nevertheless, the results obtained using gene modified mice and the 
anti-CCRL2 moAb candidate this receptor as a potential target for inhibiting neutrophil sustained 
inflammatory conditions. 
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Figure legends  
Figure 1. Defective neutrophil recruitment in CCRL2-deficient mice 
(A) Cytofluorimetric profiles of CXCR2 and CCRL2 expression in bone marrow purified (BM) 
neutrophils from WT and CCRL2-deficient mice (CCRL2 KO) stimulated with TNFα (20 ng/ml), 
LPS (100 ng/ml), a combination of TNFα, LPS and 50 ng/ml IFNγ (MIX) or medium for 18 hrs. 
Cells were stained with a rat anti-mouse CCRL2 moAb followed by an anti-rat PE moAb; and with 
a rat anti-mouse CXCR2-Alexa Flour 647 moAb. Representative plots from 3 independent 
experiments are shown in the left panel; right panels show summarized results of single CXCR2 
and CCRL2 staining (* P<0.05 by Student t-test). (B-C) Peritoneal recruited cells from WT and 
CCRL2 KO mice injected i.p. with LPS (15 ng/mouse) for 2 hrs (B) or CXCL8 (300 ng/mouse) for 
4 hrs (C). Control mice received sterile phosphate buffered saline (saline). The number of 
CD11b+Ly6G+ neutrophils/mouse was evaluated by FACS analysis. The results are expressed as 
mean ± SEM of 3 independent experiments for a total of 10 mice/group. In panel B, the right graph 
shows MFI values of CCRL2 expression by neutrophils collected 2 hrs after LPS or saline injection. 
* P<0.05 by Student t-test. (D) Synovial cavity recruited cells at the indicated time points after the 
injection of methylated bovine serum albumin (metBSA) or saline into the knee joints of metBSA-
immunized mice. Results are expressed as mean + SEM of 3 independent experiments (n=14); 
*P<0.05, **P<0.01 by Student t- test. 
  
Figure 2. CCRL2-deficient mice are protected in collagen-induced arthritis (CIA)  
(A) Clinical score of Collagen-induced arthritis (CIA) in WT and CCRL2-deficient (KO) mice 
immunized with chicken type II collagen. Scores from four paws were combined for each mouse, 
and total severity score for the group was divided by the number of arthritic mice to obtain an 
average severity score (clinical score 0–16 in the four paws). Data are shown as mean + SEM from 
one representative experiment performed out of three (WT n=29; CCRL2 KO n=24 mice); 
***P<0.001, WT vs. CCRL2 KO mice by two-way ANOVA. (B) Histopathology of a 
representative arthritic joint from WT and CCRL2 KO mice (magnification 4x). (C) 
Histopathological score of arthritic mice as evaluated for leukocyte infiltration, erosion, pannus, 
necrosis/fibrosis, loss of cartilage and bone integrity. Data are shown as mean + SEM of arthritic 
scores of one representative experiment (WT, n=8; CCRL2 KO, n=10); **P<0.01, by Mann 
Whitney test. (D) Levels of total anti-collagen II IgG (μg/ml) measured in mouse sera at the end of 
the experiment (day +60).  
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Figure 3. CCRL2-deficient mice are protected in experimental inflammatory arthritis  
(A) Clinical score of CIA in DBA1 mice treated three times a week with anti-CCRL2 or isotype 
control antibody (Iso Ctr) (100μg/mouse i.p.) starting the day before the first immunization with 
bovine type II collagen. One representative experiment out of two is shown; *** P<0.001 
DBA1+anti-CCRL2 vs. DBA1+Iso Ctr by two-way ANOVA (n=10 per group). (B) Clinical score 
of serum transfer-induced arthritis (STIA) determined in CCRL2 KO, WT, and anti-CCRL2 
antibody-treated WT mice (anti-CCRL2) (100 μg/mouse from day 0 to day4). STIA was induced by 
injection of 150 μl of K/BxN serum at day 0 (n=5 per group). Clinical score was daily assessed. 
One representative experiment out of three is shown; *** P<0.001, WT vs. CCRL2 KO or anti-
CCRL2 group by two-way ANOVA. (C) For Ly6G staining, hyaluronidase-treated tissue sections 
were stained with a rat anti-mouse Ly6G antibody (BD Biosciences). Left panel: quantitative 
analysis of immunohistochemical staining for Ly6G+ cells/mm2 of joint sections scanned by VS120 
Dot-Slide BX61 VS (Olympus Optical) and analyzed using Image Pro-Premiere software (Media 
Cybernetics). *P<0.05, **P<0.01 by one way ANOVA (n=6 mice per group). Right panel: 
representative images of Ly6G staining of arthritic joints from WT, anti-CCRL2 moAb-treated WT 
and CCRL2 KO mice (magnification 10x, and insets 20x). (D) Circulating levels of IL-6, CXCL1, 
CXCL2, CCL5 and chemerin in sera of WT and CCRL2-deficient mice at day +4 of STIA by 
Luminex Multiplex assay. (E) Clinical score of WT or CCRL2 KO mice receiving bone marrow 
neutrophils (PMN; 5x106/mouse/day) from WT and CCRL2 KO mice in STIA model. Data (n=5 
per group) from one representative experiment out of three are shown; *P<0.05 PMN WT in WT or 
PMN WT in KO, or PMN KO in WT vs. PMN KO in KO by two-way ANOVA.  
 
Figure 4. Defective CXCL8-dependent β2-integrin activation and signaling in CCRL2-
deficient mice 
(A) Intravital microscopy of the interaction between leukocytes and endothelial cells in the synovial 
microvasculature in WT and CCRL2-deficient mice (KO) previously immunized with metBSA. A 
leukocyte was considered adherent when stationary for at least 30 seconds, and total leukocyte 
adhesion was quantified as the number of adherent cells within a 100-μm length of venule in 5 min. 
Left panel, representative images captured after saline (right) and antigen (left) injection into the 
knees. Scale bar=20 μm. Right panel, quantitative analysis of cells adherent to the synovial 
endothelium. ***P<0.001, by Student t-test, n=7 mice/group. (B) Under flow adhesion of freshly 
BM-purified neutrophils from WT and CCRL2-deficient mice (KO) to immobilized E-selectin, 
ICAM-1, and CXCL8. Where indicated, WT neutrophils were pretreated with an anti-CCRL2, or 
isotype control, moAb for 30 minutes. The behavior of interacting neutrophils was recorded on 
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digital drive with fast CCD video camera (25 frames/s, capable of 1/2 subframe 20 msec recording) 
and analyzed subframe by subframe. Single areas of 0.2 mm2 were recorded for at least 60 sec. 
Interactions of 40 ms or longer were considered significant and scored 24. Cells that remained firmly 
adherent for at least 1 sec were considered fully arrested. Cells arrested for at least 1 sec and then 
detached, or for 10 s and then remained adherent, were scored separately and plotted as independent 
groups. Data are shown as mean + SEM of three experiments performed in triplicates; ***P<0.001 
WT vs. CCRL2 KO or WT+anti-CCRL2 by Student t-test. (C) ERK1/2 phosphorylation evaluated 
in CD11b+/Ly6G+-gated freshly isolated bone marrow cells stimulated with 100 ng/ml CXCL8 at 
the indicated time points. Results are expressed as % of increase of MFI of stimulated over 
unstimulated cells. The mean + SEM of 8 mice per group in duplicates is shown. * P<0.05 by 
Student t-test. The activation of RhoA (D) and Rac1 (E) was evaluated in CD11b+/Ly6G+-gated 
freshly isolated bone marrow cells. Data are expressed as fold of increase of MFI of CXCL8 100 
ng/ml stimulated over unstimulated cells (time 0) at the indicated time points. The mean + SEM of 
10 (RhoA) and 8 (Rac1) mice per group are shown. *P<0.05, **P<0.01 by Student t-test. (F) 
Calcium fluxes of CXCL8-stimulated WT and CCLR2-deficient neutrophils. Fluo-8 NW-loaded 
freshly isolated BM neutrophils were exposed to increasing concentrations CXCL8, calcium traces 
are reported as ΔF/F0 above time (left two panels), where ΔF/F0 is the difference between the RFU 
and the basal fluorescence at time 0 (F0), normalized for F0. Each curve represents the mean of 4 
replicate wells. Right panel: concentration-response curves obtained calculating the calcium 
response as ΔF/F0, where ΔF represents the difference between the maximum fluorescence signal in 
a selected time window (9-65 sec) and the minimum fluorescence signal occurring at sec 11, 
normalized for the basal fluorescence at time zero (F0). EC50 values were 125 nM and 251 nM for 
WT and CCLR2-deficient neutrophils, respectively. Data are shown as mean ± SEM, (n=4); 
p<0.0001 by Student t-test. 
 
Figure 5. Role of CCRL2 in neutrophil functions 
 (A) Elastase release of WT and CCRL2-deficient neutrophils in response to CXCL8 and CXCL1 
evaluated as elastase activity in cell supernatants. Representative results of one out of three 
independent experiments performed in triplicate are shown as the mean ± SEM; **P<0.01 by 
Student t-test. (B) Migration of BM neutrophils in response to LTB4 (100 nM), PAF (100 nM), 
CXCL1 (100 ng/ml), CXCL8 (100 ng/ml), CCL3 (100 ng/ml), chemerin (100 pM) evaluated in 
Boyden chambers as previously described55. Results are expressed as the mean number of migrated 
cells in five high-power fields (100x). Data are shown as the mean + SEM of three independent 
experiments performed in triplicate. (C) Migration of BM-purified neutrophils from WT or 
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CCRL2-deficient (KO) mice assessed by time-lapse microscopy. Representative tracking analyses 
of resting WT and CCRL2-deficient neutrophils in response to CXCL8 are shown in the left panel. 
Single cell speed toward CXCL8 of cells stimulated with LPS (100ng/ml) or left untreated in shown 
in the right panel. Single cell directionality and speed were analyzed with ImageJ software and data 
were re-elaborated using the open source software TimeLapseAnalyser available at 
http://www.informatik.uni-ulm.de/ni/staff/HKestler/tla/.  In the right panel, the mean + SEM of the 
speed recorded in three independent experiments is shown, *P<0.05 by one way ANOVA.  
 
Figure 6. CCRL2 and CXCR2 form homo- and heterodimers in living cells 
FRET saturation curves for CXCR2/CXCR2 (A), CCRL2/CCRL2 (B), and CXCR2/CCRL2 (C) 
complexes in HEK293T cells. Curves were obtained using cells transiently cotransfected with either 
the vector encoding CXCR2-CFP and increasing amounts of CXCR2-YFP plasmid, or the CCRL2-
CFP plasmid and increasing amounts of CCRL2-YFP plasmid. For heterodimer evaluation, we used 
CXCR2-CFP plasmid and increasing amounts of CCRL2-YFP plasmid. For negative controls, cells 
were transfected with CXCR2-CFP or CCRL2-CFP plasmid and increasing amounts of H3R-YFP 
plasmid. Using ImageJ 1.43u software (NIH), FRET efficiency was determined on a pixel-by-pixel 
basis (E) and calculated in percent as E = [(ICFPpost - ICFPpre)/ICFPpost] x 100, where ICFPpre 
and ICFPpost are the background-corrected CFP fluorescence intensities before and after YFP 
photobleaching, respectively. FRET efficiency was calculated from ≥20 images from each of three 
independent experiments. Data are expressed as the mean + SEM of five independent experiments 
performed in duplicate. FRET50 and FRETmax value were calculated using a nonlinear regression 
equation for a single binding site model, and are expressed as mean ± SEM (n=5). (D) FRET 
analysis by acceptor photobleaching of CXCR2/CCRL2 heterodimers. Representative images are 
shown of CFP and YFP staining before photobleaching (CFP-pre, YFP-pre), as well as of CFP and 
YFP after photobleaching (CFP-post, YFP-post) and a zoom image of FRET at the photobleached 
areas (1 and 2) using a false color scale (inset). Only areas with a ~2:1 YFP:CFP ratio were selected 
for bleaching analysis (white outline). Areas in which the YFP:CFP ratio was unsuitable were not 
included in the analysis. In area 2, red dashed line indicates the position of the cell membrane. 
Percentage of FRET efficiency ± SEM is shown for each photobleached area. (E) Membrane 
expression of CXCR2 in HEK293T cells transfected with CXCR2 alone (empty vector) or plus 
CCRL2 was determined by flow cytometry analysis using specific anti-CXCR2 moAb. Data are 
expressed as the mean ± SEM of three independent experiments performed in duplicate, *P<0.05 by 
Student t-test. (F) Membrane expression of CXCR2 on CD11b+Ly6G+ BM-purified neutrophils 
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from WT and CCRL2-deficient mice. Data are expressed as relative MFI (mean + SEM of 6 mice 
per group). *P<0.05, by Student t-test. 
 
Figure 7. CCRL2 expression modulates the CXCR2 homodimeric conformation 
(A) Membrane expression of CCRL2 in HEK293T cells transiently cotransfected with empty 
pcDNA3.1 (grey) or pcDNA3.1CCRL2+CXCR2-CFP/CXCR2-YFP (open) at a ratio of ∼5 was 
determined by flow cytometry. CCRL2 expression is shown at a representative ratio of the curve, 
and is maintained at all ratios tested. (B) HEK293T cells were transiently transfected with 
pcDNA3.1 or pcDNA3.CCRL2. At 24 hrs post-transfection, the cells were cotransfected with a 
constant amount of CXCR2-CFP and increasing amounts of CXCR2-YFP. A representative 
experiment is shown. (C) FRETmax and FRET50 values were deduced from data analysis using 
nonlinear regression equation applied to a single binding site model and are representative of four 
independent experiments. Data are expressed as mean ± SEM. FRET50 values from cells co-
expressing CXCR2-CFP/CXCR2-YFP + CCRL2 were significantly decreased in the four 
experiments compared with CXCR2-CFP/CXCR2-YFP+pcDNA3.1, *P <0.05 Student t-test.  
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